



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2011

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 12/31/2011 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 12/31/2010 RM'000	CURRENT YEAR TO DATE 12/31/2011 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 12/31/2010 RM'000
Revenue	33,036	32,195	138,132	131,437
Cost of Sales	(15,817)	(16,119)	(74,847)	(71,940)
Gross Profit	17,219	16,076	63,285	59,497
Other operating income	69	54	247	183
Distribution costs	(4,189)	(3,600)	(12,415)	(12,265)
Administration expenses	(3,437)	(2,831)	(12,871)	(9,569)
Other operating expenses	(1,730)	(1,197)	(3,612)	(2,886)
Profit from operations	7,932	8,502	34,634	34,960
Finance income	42	115	365	490
Finance costs	(138)	(10)	(271)	(42)
Profit before taxation	7,836	8,607	34,728	35,408
Taxation	(1,507)	7	(8,023)	(6,739)
Profit after tax for the period	6,329	8,614	26,705	28,669
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	6,329	8,614	26,705	28,669
Profit attributable to:				
Shareholders of the Company	6,329	8,614	26,705	28,669
Minority interest	-	-	-	-
	6,329	8,614	26,705	28,669
Total other comprehensive income attributable to:				
Shareholders of the Company	6,329	8,614	26,705	28,669
Minority interest	-	-	-	-
	6,329	8,614	26,705	28,669
Earnings per share (sen)				
Basic (based on weighted average)	4.56	6.21	19.24	20.65
Diluted (based on weighted average)	4.56	6.21	19.24	20.65

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2011

	AS AT 31/12/2011 RM'000	AS AT 31/12/2010 RM'000
ASSETS		
Property, Plant and Equipment	95,981	100,249
Investment properties	5,716	-
Total non-current assets	101,697	100,249
Inventories	45,124	34,003
Trade & Other Receivables	36,490	34,804
Amount Due From Related Company	769	951
Current tax assets	2,695	-
Assets classified as held for sale	1,740	1,740
Cash & Cash Equivalents	8,584	24,732
Total current assets	95,402	96,230
Total Assets	197,099	196,479
EQUITY		
Share Capital	69,739	69,739
Reserves	96,284	89,708
Treasury Shares	(1,578)	(1,578)
Total Equity	164,445	157,869
LIABILITIES		
Deferred Tax Liability	5,584	3,821
Borrowings	2,081	10,416
Total non-current liabilities	7,665	14,237
Trade & Other Payables	14,489	13,509
Amount due to related company	1,400	1,324
Provision	766	850
Taxation	-	356
Borrowings	8,334	8,334
Total current liabilities	24,989	24,373
Total Liabilities	32,654	38,610
Total Equity & Liabilities	197,099	196,479
Net assets per share (RM)	1.18	1.13

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2011

	31 December 2011	31 December 2010
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	34,728	35,408
Adjustments for:		
Depreciation of property, plant and equipment	5,969	5,441
Interest income	(365)	(490)
Finance costs	271	42
<i>Operating profit before changes in working capital</i>	<u>40,603</u>	<u>40,401</u>
Change in inventories	(11,122)	2,351
Change in receivables, deposits and prepayments	(1,959)	1,174
Change in payables and accruals	1,427	3,123
<i>Cash generated from operations</i>	<u>28,949</u>	<u>47,049</u>
Finance costs paid	(271)	(42)
Interest income	365	490
Income tax paid	(9,311)	(6,966)
 Net cash generated from operating activities	 <u>19,732</u>	 <u>40,531</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(7,417)	(25,901)
Proceed from disposal of property, plant and equipment	-	256
 Net cash used in investing activities	 <u>(7,417)</u>	 <u>(25,645)</u>
Cash flows from financing activities		
Drawdown of borrowings	-	9,574
Repayment of borrowings	(8,334)	(6,251)
Dividends paid to shareholders of the Company	(20,129)	(20,476)
 Net cash used in financing activities	 <u>(28,463)</u>	 <u>(17,153)</u>
 Net decrease in cash and cash equivalents	 (16,148)	 (2,267)
Cash and cash equivalents at 1 January	24,732	26,999
 Cash and cash equivalents as at 31 December	 <u>8,584</u>	 <u>24,732</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)